Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]"
publishDate:"[2020 TO 2020]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+hidradenitis+suppurativa+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10020041Term%3A+Hidradenitis+suppurativaSystem+Organ+Class%3A+100000004858%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Skin+and+Connective+Tissue+Diseases+%5BC17%5D%22&filter%5B%5D=publishDate%3A%22%5B2020+TO+2020%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+hidradenitis+suppurativa+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10020041Term%3A+Hidradenitis+suppurativaSystem+Organ+Class%3A+100000004858%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Skin+and+Connective+Tissue+Diseases+%5BC17%5D%22&filter%5B%5D=publishDate%3A%22%5B2020+TO+2020%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+hidradenitis+suppurativa+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10020041Term%3A+Hidradenitis+suppurativaSystem+Organ+Class%3A+100000004858%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Skin+and+Connective+Tissue+Diseases+%5BC17%5D%22&filter%5B%5D=publishDate%3A%22%5B2020+TO+2020%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (12)
1
A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
2
A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
3
A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
4
A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
5
A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) : A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNRISE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
6
A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) : A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNRISE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
7
A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) : A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNSHINE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
8
A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) : A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNSHINE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
9
A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
10
A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Filter aufheben
Erscheinungsjahr: 2020-2020
Medienart
12
Aufsätze
12
E-Artikel
12
E-Ressourcen
Zeitschriftentitel
12
WHO International Clinical Trials Registry Plat...
Thema
12
610
Medical Condition: hidradenitis suppurativa Med...
12
Phase: Phase 3
12
Recruitment Status: Authorised-recruitment may ...
12
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2020-2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
12
Englisch
Haven't found what you're looking for?
Wird geladen...